The 36-month beta value for VAXX is at 2.57. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VAXX is 45.31M, and currently, shorts hold a 9.01% of that float. The average trading volume for VAXX on April 19, 2024 was 436.22K shares.
VAXX) stock’s latest price update
The stock price of Vaxxinity Inc (NASDAQ: VAXX) has jumped by 11.20 compared to previous close of 0.42. Despite this, the company has seen a fall of -11.97% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-28 that Presentation will address the Company’s clinical data in Parkinson’s disease Presentation will address the Company’s clinical data in Parkinson’s disease
VAXX’s Market Performance
Vaxxinity Inc (VAXX) has seen a -11.97% fall in stock performance for the week, with a -36.76% decline in the past month and a -35.44% plunge in the past quarter. The volatility ratio for the week is 19.63%, and the volatility levels for the past 30 days are at 11.31% for VAXX. The simple moving average for the past 20 days is -25.38% for VAXX’s stock, with a -62.69% simple moving average for the past 200 days.
Analysts’ Opinion of VAXX
Many brokerage firms have already submitted their reports for VAXX stocks, with Robert W. Baird repeating the rating for VAXX by listing it as a “Outperform.” The predicted price for VAXX in the upcoming period, according to Robert W. Baird is $7 based on the research report published on September 08, 2023 of the previous year 2023.
VAXX Trading at -31.91% from the 50-Day Moving Average
After a stumble in the market that brought VAXX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.01% of loss for the given period.
Volatility was left at 11.31%, however, over the last 30 days, the volatility rate increased by 19.63%, as shares sank -34.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.75% lower at present.
During the last 5 trading sessions, VAXX fell by -12.88%, which changed the moving average for the period of 200-days by -81.67% in comparison to the 20-day moving average, which settled at $0.6107. In addition, Vaxxinity Inc saw -45.32% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VAXX starting from Prime Movers Lab Fund I LP, who sale 25,089 shares at the price of $1.67 back on Sep 08 ’23. After this action, Prime Movers Lab Fund I LP now owns 8,713,663 shares of Vaxxinity Inc, valued at $41,899 using the latest closing price.
Prime Movers Lab Fund I LP, the 10% Owner of Vaxxinity Inc, sale 22,872 shares at $1.67 during a trade that took place back on Sep 08 ’23, which means that Prime Movers Lab Fund I LP is holding 831,658 shares at $38,196 based on the most recent closing price.
Stock Fundamentals for VAXX
The total capital return value is set at -2.18. Equity return is now at value -150.65, with -75.49 for asset returns.
Based on Vaxxinity Inc (VAXX), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -3.77. The debt to equity ratio resting at 1.13. The interest coverage ratio of the stock is -83.81.
Currently, EBITDA for the company is -56.05 million with net debt to EBITDA at -0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.89.
Conclusion
In conclusion, Vaxxinity Inc (VAXX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
